(Q33402867)

26 July 2017

title

Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation (English)

1 reference

26 July 2017

Veysel Sabri Hancer

3

0 references

author name string

F Semsa Cayci

1

1 reference

26 July 2017

Nilgun Cakar

2

1 reference

26 July 2017

Nermin Uncu

4

1 reference

26 July 2017

Banu Acar

5

1 reference

26 July 2017

Gokce Gur

6

1 reference

26 July 2017

publication date

19 August 2012

1 reference

26 July 2017

1 reference

26 July 2017

volume

27

1 reference

26 July 2017

issue

12

1 reference

26 July 2017

page(s)

2327-2331

1 reference

aHUS caused by complement dysregulation: new therapies on the horizon

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2283-9

A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2283-9

Complement factor I in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2283-9

Hemolytic uremic syndrome: new developments in pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2283-9

Hemolytic uremic syndrome associated with Entamoeba histolytica intestinal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2283-9

Advances in understanding the aetiology of atypical Haemolytic Uraemic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2283-9

Hemolytic uremic syndrome due to homozygous factor H deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2283-9

Complement inhibitor eculizumab in atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2283-9

What's new in haemolytic uraemic syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2283-9

Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2283-9

Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2283-9

Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2283-9

Eculizumab in severe Shiga-toxin-associated HUS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2283-9

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22903728

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22903728

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00467-012-2283-9

1 reference

Dimensions Publication ID

26 July 2017

1027856868

0 references

1 reference